Acurian, Inc. Receives 2016 Eli Lilly Global Supplier Award

INDIANAPOLIS--(BUSINESS WIRE)--Acurian Inc., a leading, full-service provider of global patient enrollment and retention solutions and a subsidiary of PPD, was selected by Eli Lilly and Company (NYSE: LLY) for its 2016 Lilly Global Supplier Award. Lilly presented the award to Acurian in a ceremony at the company’s headquarters in Indianapolis on May 12.

“This award recognizes our company’s ability to provide enrollment solutions that are designed to increase the efficiency and cost-effectiveness of clinical development, without sacrificing the quality of trial data.”

The Lilly Global Supplier Award recognizes suppliers who have worked collaboratively to deliver a positive and measurable impact on Lilly’s corporate objectives and priorities. The annual award is given to suppliers who exemplify the delivery of quality, service, speed, total cost reduction and value.

“We are exceptionally honored to receive this award for the second time in the past five years,” said Roger Smith, Acurian senior vice president and general manager. “This award recognizes our company’s ability to provide enrollment solutions that are designed to increase the efficiency and cost-effectiveness of clinical development, without sacrificing the quality of trial data.”

About Acurian

Acurian, a subsidiary of PPD, is a leading full-service provider of clinical trial patient enrollment and retention solutions for the life sciences industry. The company increases the enrollment performance of investigator sites worldwide by identifying, contacting, prescreening and referring people who live in the local community but are unknown to a research site. As a result, trial sponsors complete enrollment without incurring the unexpected expense of adding sites or time.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about Acurian’s service offerings and expertise, including outside the United States, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD and Acurian attempt to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development and privacy laws and regulations; changes in the regulation of the drug development process and privacy laws and regulations; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD and Acurian do not assume any obligation and expressly disclaim any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s or Acurian’s estimates or views as of any date subsequent to the date hereof.